ArticleCirculation2024
Development and Validation of the American Heart Association's PREVENT Equations.
Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07791589 (Fibrosis Versus Metabolic Risk in MASLD), which is not on this map. Cited by 561 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fibrosis Versus Metabolic Risk in MASLD: Age-Adjusted Associations With PREVENT Cardiovascular Risk
Who cites it
561 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Cardiovascular Efficacy of GLP-1 Receptor Agonists by Kidney Function: An Updated Meta-Analysis of Randomized Trials Including the SOUL Trial.Diabetes, obesity & metabolism · 2026Pooled it
- A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.PharmacoEconomics · 2026Pooled it
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2026Guideline
- Characteristics of Cardiovascular Disease Prediction Models Considering Mental Disorders: A Systematic Review.Journal of the American Heart Association · 2026Pooled it
- Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.JACC. Heart failure · 2026Guideline
- Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Circulation. Heart failure · 2026Trial
- Danish evaluation of Your Heart Forecast: a cluster randomised controlled trial aimed at improving modifiable risk factors of CVD.Open heart · 2026Trial
- Association of nephrolithiasis history with adverse outcomes in cardiovascular-kidney-metabolic syndrome.Renal failure · 2026Article
- Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction.Annals of medicine · 2026Review
- Depression and risk of incident heart diseases among older adults at CKM stages 0-3: evidence from the China Health and Retirement Longitudinal Study.Annals of medicine · 2026Article
- Genetic and clinical risk factors for recurrent events among patients with coronary artery disease.American journal of preventive cardiology · 2026Article
- Associations of the PREVENT Score with coronary artery and thoracic aortic calcification among South Asian Americans.American journal of preventive cardiology · 2026Article
- Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes.American journal of preventive cardiology · 2026Article
- PREVENT vs PCE thresholds for coronary artery calcium referral: Detection-optimized strategies in ELSA-Brasil.American journal of preventive cardiology · 2026Article
- Commentary - genetic susceptibility as a risk enhancer in secondary prevention: Contextualizing the CAD polygenic risk score.American journal of preventive cardiology · 2026Article
- The impact of adherence to a DASH diet pattern on pharmacotherapy initiation in stage 1 hypertension.American journal of preventive cardiology · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome: Conceptualising an Approach to Health Economic Modelling.Diabetes, obesity & metabolism · 2026Review
- Current attitudes of primary care providers toward albuminuria testing in patients with diabetes in the United States.Preventive medicine reports · 2026Article
- Three-year cardiovascular risk prediction among people who use cocaine or methamphetamine.Drug and alcohol dependence reports · 2026Article
- Long-term cardiovascular risk with cardiovascular-kidney-metabolic syndrome in U.S adults.American heart journal plus : cardiology research and practice · 2026Article
501 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
28 authors.
Funding
Abstract
backgroundMultivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD.
methodsThe derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets.
resultsAmong 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65];
conclusionsPREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.